Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overcoming resistance to targeted therapy for lung cancer.

× No keyword cloud information.

14 in total

1. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.

Authors: Shao-Bo Ke; Hu Qiu; Jia-Mei Chen; Wei Shi; Yong-Shun Chen
Journal: Curr Med Sci Date: 2018-12-07

2. JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells.

Authors: Zhenzhen Pan; Qiufang Chen; Xiulan Zheng; Kai Wang; Yalei Duan; Kang Xiao; Zhirong Jia; Xuansheng Ding
Journal: Onco Targets Ther Date: 2020-07-31 Impact factor: 4.147

3. Does osimertinib treatment discriminate young patients?

Authors: Cheng Ji; Chongke Zhong; Shi-Yong Sun
Journal: J Thorac Dis Date: 2019-09 Impact factor: 2.895

4. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).

Authors: Hongjing Zang; Guoqing Qian; Dan Zong; Songqing Fan; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal: Cancer Date: 2020-01-30 Impact factor: 6.860

Review 5. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.

Authors: Yuli Wang; Zhitao Guo; Yang Li; Qinghua Zhou
Journal: Open Med (Wars) Date: 2016-03-26

6. Lung Nodule Malignancy Prediction in Sequential CT Scans: Summary of ISBI 2018 Challenge.

Authors: Yoganand Balagurunathan; Andrew Beers; Michael Mcnitt-Gray; Lubomir Hadjiiski; Sandy Napel; Dmitry Goldgof; Gustavo Perez; Pablo Arbelaez; Alireza Mehrtash; Tina Kapur; Ehwa Yang; Jung Won Moon; Gabriel Bernardino Perez; Ricard Delgado-Gonzalo; M Mehdi Farhangi; Amir A Amini; Renkun Ni; Xue Feng; Aditya Bagari; Kiran Vaidhya; Benjamin Veasey; Wiem Safta; Hichem Frigui; Joseph Enguehard; Ali Gholipour; Laura Silvana Castillo; Laura Alexandra Daza; Paul Pinsky; Jayashree Kalpathy-Cramer; Keyvan Farahani
Journal: IEEE Trans Med Imaging Date: 2021-11-30 Impact factor: 11.037

Review 7. The distinctive nature of adenocarcinoma of the lung.

Authors: Giandomenico Roviello
Journal: Onco Targets Ther Date: 2015-09-02 Impact factor: 4.147

8. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Authors: Yongshun Chen; Jing Yang; Xue Li; Daxuan Hao; Xiaoyuan Wu; Yuanyuan Yang; Chunyu He; Wen Wang; Jianhua Wang
Journal: Cancer Sci Date: 2016-11-25 Impact factor: 6.716

Review 9. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.

Authors: Shang-Gin Wu; Jin-Yuan Shih
Journal: Mol Cancer Date: 2018-02-19 Impact factor: 27.401

10. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis.

Authors: Hualin Chen; Aibing Wu; Hua Tao; Donghong Yang; Yiping Luo; Shujun Li; Zhixiong Yang; Ming Chen
Journal: Medicine (Baltimore) Date: 2018-11 Impact factor: 1.817